Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Til Menge

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
MMW Fortschritte Der Medizin|August 7, 2024
Til Menge
MMW Fortschritte Der Medizin|November 22, 2024
Til Menge
MMW Fortschritte Der Medizin|April 16, 2025
Til Menge
Immunobiology|May 10, 2002
Monoclonal autoantibodies from patients with autoimmune diseases: specificity, affinity and crossreactivity of MAbs binding to cytoskeletal and nucleolar epitopes, cartilage antigens and mycobacterial heat-shock protein 60Til Menge, Rita Rzepka, Inga Melchers
Nature Reviews. Neuroscience|April 2, 2005
Statins--a cure-all for the brain?Til Menge, Hans-Peter Hartung, Olaf Stüve
Journal of Neurology|February 23, 2011
Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et alTil Menge, Hans-Peter Hartung, Bernd C Kieseier
Handbook of Clinical Neurology|February 11, 2014
Immune regulation of multiple sclerosisHans-Peter Hartung, Orhan Aktas, Til Menge, et al.
Neurology|June 13, 2014
Alemtuzumab: the advantages and challenges of a novel therapy in MSTil Menge, Olaf Stüve, Bernd C Kieseier, et al.
Qatar Medical Journal|November 29, 2023
Immunomodulatory potential of anti-IFN-beta antibodies on monocyte-derived macrophagesAjith Sominanda, Til Menge, Hans Peter Hartung, et al.
Expert Review of Neurotherapeutics|August 24, 2016
Ocrelizumab for the treatment of relapsing-remitting multiple sclerosisTil Menge, Divyanshu Dubey, Clemens Warnke, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
MMW Fortschritte Der Medizin|August 7, 2024
Til Menge
MMW Fortschritte Der Medizin|November 22, 2024
Til Menge
MMW Fortschritte Der Medizin|April 16, 2025
Til Menge
Immunobiology|May 10, 2002
Monoclonal autoantibodies from patients with autoimmune diseases: specificity, affinity and crossreactivity of MAbs binding to cytoskeletal and nucleolar epitopes, cartilage antigens and mycobacterial heat-shock protein 60Til Menge, Rita Rzepka, Inga Melchers
Nature Reviews. Neuroscience|April 2, 2005
Statins--a cure-all for the brain?Til Menge, Hans-Peter Hartung, Olaf Stüve
Journal of Neurology|February 23, 2011
Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et alTil Menge, Hans-Peter Hartung, Bernd C Kieseier
Handbook of Clinical Neurology|February 11, 2014
Immune regulation of multiple sclerosisHans-Peter Hartung, Orhan Aktas, Til Menge, et al.
Neurology|June 13, 2014
Alemtuzumab: the advantages and challenges of a novel therapy in MSTil Menge, Olaf Stüve, Bernd C Kieseier, et al.
Qatar Medical Journal|November 29, 2023
Immunomodulatory potential of anti-IFN-beta antibodies on monocyte-derived macrophagesAjith Sominanda, Til Menge, Hans Peter Hartung, et al.
Expert Review of Neurotherapeutics|August 24, 2016
Ocrelizumab for the treatment of relapsing-remitting multiple sclerosisTil Menge, Divyanshu Dubey, Clemens Warnke, et al.
Pageof 5